Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell

Pyxis Oncology (NASDAQ:PYXS) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

A number of other analysts have also commented on PYXS. Stephens lifted their price target on Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Thursday, January 22nd. Royal Bank Of Canada cut their target price on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Finally, HC Wainwright boosted their target price on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pyxis Oncology currently has an average rating of “Moderate Buy” and an average target price of $7.20.

Pyxis Oncology Stock Up 0.7%

Shares of PYXS stock opened at $1.54 on Friday. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55. The stock’s fifty day simple moving average is $1.53 and its 200 day simple moving average is $2.50. The firm has a market capitalization of $95.88 million, a P/E ratio of -0.96 and a beta of 1.45.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors have recently made changes to their positions in the stock. Maia Wealth LLC acquired a new stake in shares of Pyxis Oncology in the fourth quarter valued at about $25,000. Engineers Gate Manager LP acquired a new position in shares of Pyxis Oncology in the fourth quarter worth approximately $26,000. Fox Run Management L.L.C. acquired a new position in shares of Pyxis Oncology in the fourth quarter worth approximately $26,000. Catalyst Funds Management Pty Ltd bought a new stake in Pyxis Oncology in the second quarter valued at approximately $26,000. Finally, Avanza Fonder AB bought a new stake in Pyxis Oncology in the fourth quarter valued at approximately $31,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.